{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:29:18Z","timestamp":1730870958385,"version":"3.28.0"},"reference-count":12,"publisher":"Georg Thieme Verlag KG","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            SARS-CoV-2 Im Zuge der COVID-19-Pandemie wurden erstmalig Impfstoffe zugelassen, die auf der mRNA-Technologie beruhen. Dabei kodiert die mRNA f\u00fcr das virale Spike-Protein und es kommt nach der Impfung zur Ausbildung von spezifischen Antik\u00f6rpern und T-Zellen, welche einen sehr wirksamen Schutz gegen eine schwere Erkrankung und Tod infolge von COVID-19 bewirken. Aufgrund von genetischer Variabilit\u00e4t und rascher Evolution des SARS-CoV-2-Virus entstehen regelm\u00e4\u00dfig neue Virusvarianten. Die verf\u00fcgbaren Impfstoffe k\u00f6nnen vergleichsweise schnell an die saisonal dominierenden Virusvarianten angepasst werden. F\u00fcr die kommende Wintersaison werden mRNA-Impfstoffe gegen die SARS-CoV-2-Omicron-Sublinie JN.1 empfohlen.<\/jats:p><jats:p>\n            Saisonale Influenza Saisonale Influenzaviren ver\u00e4ndern sich saisonal erheblich in ihren antigenen Eigenschaften, sodass j\u00e4hrlich ver\u00e4nderte Impfstoffe zur Auffrischung gegeben werden. Die WHO trifft jeweils im Fr\u00fchjahr eine Vorhersage und spricht eine Empfehlung f\u00fcr die Hersteller aus, welche genetischen H\u00e4magglutinin- und Neuraminidase-Varianten f\u00fcr den saisonalen Influenzaimpfstoff ber\u00fccksichtigt werden sollen. Bislang wurden quadrivalente Impfstoffe empfohlen. F\u00fcr die Saison 2024\/2025 auf der Nordhalbkugel wurden trivalente Impfstoffe empfohlen, da seit 2020 die Influenza-B-\/Yamagata-Linie nicht mehr zirkuliert. F\u00fcr die Altersgruppe &gt;60 Jahre ist ein Hochdosis-Impfstoff mit der 4-fachen Antigenmenge empfohlen, der in dieser Altersgruppe eine leichtgradig verbesserte Wirksamkeit zeigt.<\/jats:p>","DOI":"10.1055\/a-2115-0404","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T22:34:36Z","timestamp":1723761276000},"page":"1045-1049","source":"Crossref","is-referenced-by-count":0,"title":["Impfen bei pneumologischen Erkrankungen \u2013 was, wann und wie?"],"prefix":"10.1055","volume":"149","author":[{"given":"Cathrin","family":"Kodde","sequence":"additional","affiliation":[{"name":"F\u00e4cherverbund f\u00fcr Infektiologie, Pneumologie und Intensivmedizin, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif Erik","family":"Sander","sequence":"additional","affiliation":[{"name":"F\u00e4cherverbund f\u00fcr Infektiologie, Pneumologie und Intensivmedizin, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"},{"name":"Berlin Institute of Health, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"ref3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1055\/s-0034-1377412","article-title":"Impfungen in der Pneumologie","volume":"68","author":"C Forstner","year":"2014","journal-title":"Pneumologie"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"230034","DOI":"10.1183\/16000617.0034-2023","article-title":"The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus","volume":"32","author":"S Simon","year":"2023","journal-title":"European Respiratory Review"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1055\/a-2124-2366","article-title":"Impfungen als Schl\u00fcssel der Pandemiebew\u00e4ltigung","volume":"148","author":"NH Le","year":"2023","journal-title":"Dtsch Med Wochenschr"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e0255659","DOI":"10.1371\/journal.pone.0255659","article-title":"Reduction in hospitalised COPD exacerbations during COVID-19: a systematic review and meta-analysis","volume":"16","author":"JS Alqahtani","year":"2021","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S1473-3099(23)00746-6","article-title":"Short-term effectiveness of the XBB. 1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study","volume":"24","author":"CH Hansen","year":"2024","journal-title":"Lancet Infec Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.chest.2021.12.654","article-title":"Impaired SARS-CoV-2 mRNA vaccine antibody response in chronic medical conditions: a real-world analysis","volume":"161","author":"SY Liao","year":"2022","journal-title":"Chest"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1016\/j.vaccine.2022.04.019","article-title":"Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective\u2013A systematic review of recently published literature on real-world data","volume":"40","author":"B G\u00e4rtner","year":"2022","journal-title":"Vaccine"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"CP Arevalo","year":"2022","journal-title":"Science"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMcibr2215281","article-title":"An mRNA Influenza Vaccine \u2013 Could It Deliver?","volume":"388","author":"KM Neuzil","year":"2023","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/resp.14309","article-title":"Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations","volume":"27","author":"Y Li","year":"2022","journal-title":"Respirology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.121.057042","article-title":"Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"144","author":"O Fr\u00f6bert","year":"2021","journal-title":"Circulation"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2115-0404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:17:38Z","timestamp":1730823458000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2115-0404"}},"subtitle":["Teil 1: Covid und Influenza"],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":12,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,8,15]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2115-0404","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"type":"print","value":"0012-0472"},{"type":"electronic","value":"1439-4413"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}